Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Okays Purdue's Newer OxyContin, But Is Still Hung Up On Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee members said a newer formulation of OxyContin may deter misuse, but its safety is unclear.

You may also be interested in...



Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead

FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel